Healthcare cybersecurity · IoMT asset intelligence
Cylera
Cylera is a healthcare IoT and medical-device security platform for hospitals. It discovers connected devices, scores risk, and helps security and biomed teams prioritize remediations. It is not a clinical identity or SSO product.
Strong fit
- Hospitals that need accurate IoMT inventory before they can patch or segment
- Security and biomed teams sharing one device risk view
- Buyers comparing healthcare-specific IoT platforms instead of general OT tools
Weak fit
- Ambulatory groups with almost no connected medical devices
- Teams that only need clinical identity or SSO
- Buyers expecting a full managed SOC in the same product
Bottom line
Cylera earns a Recommend for health systems that still cannot trust their medical-device inventory. Outcomes look strongest when biomed and security share one asset and risk view and use it to prioritize remediations. Projects stall when the console sits unused. Product depth is competitive in the IoMT peer set on our board, though Claroty still leads many enterprise evaluations on CPS breadth. Implementation is lighter than a full CPS program but still needs network taps and clinical-uptime rules. Pricing is custom mid-market SaaS. Score sits with Asimily and Cynerio on IoMT-focused outcomes, below Imprivata's identity lane.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
Cylera sells real-time IoT and medical-device asset intelligence for hospitals that need to know what is on the network before they can segment or patch it. Buyers usually compare it with Claroty, Cynerio, and Asimily on inventory accuracy, clinical-device context, and how noisy the alerts feel to a thin security team.
Treat the first months as an inventory and risk-ranking exercise shared by biomed and security. Projects stall when one analyst owns the console and never gets change windows for the devices that matter.
Cylera is a weaker fit when you mainly need clinical identity (Imprivata) or when you have almost no IoMT footprint. On our cybersecurity board it scores in the IoMT cluster with Cynerio and Asimily, slightly under Claroty's broader CPS mark.
Competitor landscape
| Vendor | Overall | Ease of implementation |
|---|---|---|
| Cylera | 7.4 | 7.0 |
| Claroty | 7.5 | 7.1 |
| Cynerio | 7.3 | 7.0 |
| Asimily | 7.2 | 6.8 |
Pricing
| Item | Detail |
|---|---|
| Model | SaaS subscription sized to device or bed footprint; enterprise packaging for multi-hospital systems. |
| What usually drives cost | Connected-device count, hospital sites, and any professional services for network onboarding. |
| What to ask in diligence | Modeled annual cost at your device inventory, plus what is required for a first-site pilot before enterprise expansion. |
| Published pricing | Public list price: not published. Expect a custom quote; confirm total cost at your device volume. |
Prerequisites for purchase
| Need | Why it matters |
|---|---|
| What you need to get Cylera to function | |
| Network visibility path for clinical device VLANs | Without traffic or agent coverage, inventory stays incomplete. |
| Biomed and security owners who share remediation priorities | Split ownership leaves risky devices untouched. |
| Change windows that respect clinical uptime | Blocking devices during procedures is a failed rollout. |
| Asset inventory goals for the first sites | Unbounded enterprise rollouts hide data-quality problems. |
| A path to ticketing or CMDB handoff | Risk scores that never leave the console do not reduce exposure. |
| What will maximize your value | |
| Measure inventory completeness against biomed records | Trust collapses when known pumps are missing from the console. |
| Prioritize devices that can interrupt care if compromised | Equal-weight alert queues burn the team out. |
| Segment high-risk device classes after inventory stabilizes | Segmentation before inventory creates outages. |
| Include facilities OT only when scoped | Scope creep into building systems delays clinical wins. |
| Re-check after major device fleet refreshes | New modalities reintroduce blind spots. |
| Deal-breakers | |
| You mainly need SSO or clinical identity, not device inventory. | |
| IT cannot mirror or tap the clinical network segments that matter. | |
| Biomed will not participate in remediation prioritization. | |
| Leadership expects a full managed SOC inside the IoMT license. | |
| You have almost no connected medical devices. | |
Value creation time frame
| # | Stage | Typical range |
|---|---|---|
| 1 | Contract signed → kickoff | 2-6 weeks (security review, network architecture, pilot units) |
| 2 | Kickoff → first live workflow | 6-14 weeks for first-site inventory and risk views |
| 3 | First live workflow → steady value | 3-6 months of remediation cycles before multi-site expansion |
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category actually buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.